D.A. Davidson & CO. Acquires 70,161 Shares of Pfizer Inc. $PFE

D.A. Davidson & CO. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 2.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,138,676 shares of the biopharmaceutical company’s stock after purchasing an additional 70,161 shares during the quarter. D.A. Davidson & CO. owned about 0.06% of Pfizer worth $79,973,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. CWA Asset Management Group LLC raised its holdings in shares of Pfizer by 20.6% during the third quarter. CWA Asset Management Group LLC now owns 31,762 shares of the biopharmaceutical company’s stock worth $809,000 after acquiring an additional 5,422 shares during the period. O ROURKE & COMPANY Inc raised its position in Pfizer by 5.2% in the 3rd quarter. O ROURKE & COMPANY Inc now owns 18,045 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 887 shares during the last quarter. Park Place Capital Corp boosted its position in Pfizer by 13.7% during the 3rd quarter. Park Place Capital Corp now owns 64,446 shares of the biopharmaceutical company’s stock worth $1,642,000 after acquiring an additional 7,763 shares during the last quarter. Centennial Wealth Advisory LLC grew its stake in shares of Pfizer by 6.2% during the 3rd quarter. Centennial Wealth Advisory LLC now owns 38,064 shares of the biopharmaceutical company’s stock worth $970,000 after acquiring an additional 2,219 shares in the last quarter. Finally, Five Oceans Advisors raised its holdings in shares of Pfizer by 7.7% in the third quarter. Five Oceans Advisors now owns 8,990 shares of the biopharmaceutical company’s stock valued at $229,000 after purchasing an additional 644 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

PFE opened at $25.17 on Monday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The business has a 50 day moving average of $25.18 and a 200-day moving average of $24.92. The stock has a market cap of $143.13 billion, a price-to-earnings ratio of 14.64 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s payout ratio is presently 100.00%.

Analysts Set New Price Targets

A number of research firms recently weighed in on PFE. Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $28.06.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.